Impaired mitochondrial fatty acid synthesis leads to neurodegeneration in mice.

There has been a growing interest towards mitochondrial fatty acid synthesis (mtFAS) since the recent discovery of a neurodegenerative human disorder termed MEPAN (mitochondrial enoyl reductase protein associated neurodegeneration)， caused by mutations in the mitochondrial enoyl-CoA/ACP (acyl carrier protein) reductase (MECR) carrying out the last step of mtFAS. We show here that MECR protein is highly expressed in mouse Purkinje cells (PCs). To elucidate mtFAS function in neural tissue， we here generated a mouse line with a PC-specific knock-out (KO) of leading to inactivation of mtFAS confined to this cell type. Both sexes were studied. The mitochondria in KO PCs displayed abnormal morphology， loss of protein lipoylation and reduced respiratory chain enzymatic activities by the time these mice were 6 months of age， followed by nearly complete loss of PCs by 9 months of age. These animals exhibited balancing difficulties around 7 months of age and ataxic symptoms were evident from 8-9 months of age onwards. Our data shows that impairment of mtFAS results in functional and ultrastructural changes in mitochondria followed by death of PCs， mimicking aspects of the clinical phenotype. This KO mouse represents a new model for impaired mitochondrial lipid metabolism and cerebellar ataxia with a distinct and well-trackable cellular phenotype. This mouse model will allow the future investigation of the feasibility of metabolite supplementation approaches towards the prevention of neurodegeneration due to dysfunctional mtFAS.We have recently reported a novel neurodegenerative disorder in humans termed MEPAN (mitochondrial enoyl reductase protein associated neurodegeneration) (Heimer et al. 2016). The cause of neuron degeneration in MEPAN patients is the dysfunction of the highly conserved mitochondrial fatty acid synthesis (mtFAS) pathway due to mutations in MECR， encoding mitochondrial 2-enoyl-ACP reductase.The report presented here describes the analysis of the first mouse model suffering from mtFAS-defect-induced neurodegenerative changes due to specific disruption of the gene in PCs. Our work sheds a light on the mechanisms of neurodegeneration caused by mtFAS deficiency and provides a test bed for future treatment approaches.